A 32-year-old man from Delhi presents to the de-addiction centre with a 6-year history of heroin use. He reports using 2–3 grams daily via intranasal and occasional intravenous routes. He last used heroin 8 hours ago and now complains of severe body aches, insomnia, anxiety, and intense craving. On examination, he has dilated pupils, piloerection, lacrimation, and rhinorrhea. His vital signs show tachycardia (110/min) and hypertension (150/95 mmHg). Urine drug screen is positive for opioids. Which of the following is the most appropriate immediate pharmacological intervention?

Explanation

## Acute Opioid Withdrawal Management **Key Point:** Buprenorphine is the first-line agent for acute opioid withdrawal in most settings, especially when used early (within 12–24 hours of last use). It is a partial μ-opioid agonist with high receptor affinity and ceiling effect on respiratory depression, making it safer than full agonists. ### Why Buprenorphine Is Preferred Here 1. **Partial agonist profile:** Provides sufficient opioid effect to suppress withdrawal while minimizing overdose risk. 2. **Rapid onset:** Sublingual formulation begins working within 30–60 minutes. 3. **Flexible dosing:** Can be titrated in 2–4 mg increments based on withdrawal severity (COWS score or clinical judgment). 4. **Induction safety:** Can be started without waiting for full withdrawal (unlike naltrexone, which requires 7–10 days abstinence to avoid precipitated withdrawal). 5. **Maintenance potential:** Once stabilized, the same agent can be used for long-term maintenance. **High-Yield:** In India, buprenorphine is widely available and is the preferred induction agent for opioid use disorder per NIDA and WHO guidelines [cite:NIDA Opioid Treatment]. ### Dosing Strategy for This Patient - **Initial dose:** 8 mg sublingual (can give 4 mg initially, then 4 mg after 1–2 hours if withdrawal persists). - **Titration:** Increase by 2–4 mg every 1–3 days until withdrawal is suppressed and cravings are manageable (typical maintenance: 12–24 mg/day). - **Monitoring:** Reassess at 2 hours; if withdrawal persists, give additional 4 mg doses up to 16 mg on day 1. **Clinical Pearl:** The patient is 8 hours post-use and showing clear withdrawal signs (mydriasis, piloerection, lacrimation, rhinorrhea, tachycardia, hypertension, insomnia, anxiety). This is the ideal window for buprenorphine induction — early enough to prevent severe withdrawal, yet late enough to avoid precipitated withdrawal. ### Comparison with Other Agents | Agent | Role | Timing | Limitation | |-------|------|--------|------------| | **Buprenorphine** | First-line induction & maintenance | Start immediately (8–12 hrs post-use) | Requires sublingual administration, patient compliance | | **Methadone** | Maintenance (not induction) | Start after 24–48 hrs abstinence | Long half-life (24–36 hrs); risk of overdose if dosed too quickly; requires daily clinic visits | | **Naltrexone** | Relapse prevention (not withdrawal) | Start after 7–10 days abstinence | **Precipitates severe withdrawal if given early**; no anti-craving effect during acute phase | | **Clonidine** | Adjunctive (autonomic symptoms only) | Can start immediately | Does NOT address craving or opioid deficiency; incomplete symptom relief | **Warning:** Naltrexone is a pure antagonist and will precipitate acute, severe withdrawal if given now. Methadone is a full agonist with a long half-life and high overdose risk if dosed aggressively during induction; it is reserved for maintenance after stabilization. ## Summary Buprenorphine 8 mg sublingual is the gold standard for acute opioid withdrawal induction because it: - Suppresses withdrawal safely and rapidly. - Has a ceiling effect on respiratory depression. - Can be titrated flexibly. - Can transition seamlessly to maintenance therapy. [cite:DSM-5 Opioid Use Disorder]